CompletedNot Applicable

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

United States667 participantsStarted 2015-04-08

Plain-language summary

The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any symptoms.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically/cytologically documented DTC (papillary, follicular, Hurthle cell, and poorly differentiated carcinoma) * DTC refractory to RAI * Radiological progression and preferably according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * No symptoms due to DTC * \>/=1cm diameter of lesion confirmed by radiological exam * Life expectancy of at least 6 months Exclusion Criteria: * Plan to be treated according to a clinical trial protocol for intervention including a locoregional therapy or systemic therapy * Previous treatment with MKIs for advanced disease * Hospice patients

What they're measuring

Time to symptomatic progression (TTSP) from study entry

Timeframe: Up to 6 years

Trial details

NCT IDNCT02303444

SponsorBayer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2020-06-10

View on ClinicalTrials.gov More Thyroid Neoplasms trials